Grünenthal will also buy the worldwide rights – excluding the US and Japan – to pain-relief drug Vimovo for $115 million plus potential additional payments of up to $17 million.
The company's product is the generic version of Vimovo tablets approved by the US Food and Drug Administration (USFDA). "This launch is a testament to our core strengths in areas of research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback